BOSTON--(

波士顿--(

BUSINESS WIRE

商业热线

)--

)--

AISAP

AISAP

, a medical technology company developing AI-powered Point-of-Care Assisted Diagnosis (POCAD™) solutions to transform medical ultrasound, has partnered with Miami-based Amavita Heart and Vascular Health to offer its first-of-a-kind, AI-powered AISAP CARDIO point-of-care ultrasound (POCUS) software platform outside of hospital settings to underserved communities in South Florida.

是一家开发人工智能辅助诊断（POCAD™）解决方案以改变医学超声的医疗技术公司，该公司与总部位于迈阿密的Amavita Heart and Vascular Health合作，为佛罗里达州南部服务不足的社区提供其第一个由人工智能支持的AISAP心脏辅助诊断（POCUS）软件平台。

Amavita, led by Founder and Medical Director Pedro Martinez-Clark, MD, FACC, has begun deploying the software in screenings for aortic stenosis and other valvular diseases in its clinics, local skilled nursing facilities, and via mobile screening units in underserved communities with high minority populations..

由FACC创始人兼医学总监佩德罗·马丁内斯·克拉克（Pedro Martinez Clark，MD）领导的Amavita已经开始在其诊所、当地熟练护理机构以及少数民族人口众多的服务不足社区的移动筛查单位部署该软件，用于筛查主动脉瓣狭窄和其他瓣膜疾病。。

“Aortic stenosis is a devastating disease with a very high mortality rate if left untreated,” said Dr. Martinez-Clark. “Using AISAP CARDIO, we aim to dramatically increase early detection rates and offer patients timely intervention so that they can go on to live healthy lives. As a point-of-care assisted diagnostic, the software could revolutionize valvular and heart failure diagnoses and early treatment, as it allows us to reach out to those most in need, especially minority communities where access to timely care remains challenging.

Martinez-Clark博士说：“主动脉瓣狭窄是一种毁灭性疾病，如果不及时治疗，死亡率会很高。使用AISAP CARDIO，我们的目标是大幅提高早期发现率，并为患者提供及时干预，使他们能够继续过上健康的生活。作为一种护理辅助诊断，该软件可以彻底改变瓣膜和心力衰竭的诊断和早期治疗，因为它使我们能够接触到那些最需要帮助的人，特别是那些获得及时护理仍然具有挑战性的少数民族社区。

The impact on population health could be significant.”.

对人口健康的影响可能是巨大的。”。

To date, Dr. Martinez-Clark and his colleagues at Amavita have screened approximately 60 patients using the AISAP CARDIO. Those screenings have detected significant valvular pathologies in 28 percent of patients.

迄今为止，Amavita的Martinez Clark博士和他的同事已经使用AISAP CARDIO筛查了大约60名患者。这些筛查在28%的患者中发现了明显的瓣膜病变。

An estimated one in four patients with moderate to severe aortic stenosis goes undiagnosed, and the rates of diagnosis tend to be worse among unrepresented minority groups

据估计，每四名中度至重度主动脉瓣狭窄患者中就有一名未被诊断，在无代表性的少数群体中，诊断率往往更高

1

1

. The consequence of underdiagnosing aortic stenosis is significant, as the mortality rate of untreated disease can be as high as 50 percent within one year

。主动脉瓣狭窄诊断不足的后果很严重，因为未经治疗的疾病的死亡率在一年内可能高达50%

2

2

. Moreover, untreated cases result in approximately $10,000 in increased healthcare expenses per patient per year versus treated case

此外，与治疗病例相比，未经治疗的病例每年导致每位患者的医疗保健费用增加约10000美元

3

3

. Yet up to 50 percent of these cases are missed until post-mortem

然而，高达50%的病例直到验尸后才被遗漏

4

4

.

.

“We are grateful that Medicare and private payers in the U.S. recognize the critical human and financial impact of underdiagnosing diseases like aortic stenosis and are reimbursing for solutions like AISAP CARDIO,” added Dr. Martinez-Clark. “This is a technology that can be both life-saving for patients and game-changing for the healthcare system.”.

Martinez-Clark博士补充道：“我们很感谢美国的医疗保险和私人付款人认识到主动脉瓣狭窄等诊断不足的疾病对人类和经济的重大影响，并正在为AISAP CARDIO等解决方案进行报销。这是一项既可以挽救患者生命，又可以改变医疗保健系统游戏规则的技术。”。

“AISAP is proud to collaborate with forward-thinking practices and community partners like Amavita,” said Roni Attali, AISAP U.S. general manager and chief sales officer. “We commend Dr. Martinez-Clark on his mission to use our technology to address healthcare disparities and ensure that no patient suffering from valvular disease is left behind.”.

AISAP美国总经理兼首席销售官罗尼·阿塔利（RoniAttali）表示：“AISAP很荣幸能与具有前瞻性思维的实践和社区合作伙伴（如Amavita）合作。”。“我们赞扬Martinez Clark博士的使命，即利用我们的技术解决医疗保健差距，确保没有患有瓣膜病的患者落后。”。

AISAP CARDIO is a cloud-based platform that combines four computer-assisted diagnosis (CADx) modules of valvular pathologies and eight key measurements into a single, comprehensive, cardiac ultrasound software package that automatically generates analyses, interpretations and billable reports. CARDIO empowers clinicians with basic scanning skills to accurately diagnose up to 90 percent of the most common cardiac structural and functional parameters right at the bedside within minutes.

AISAP CARDIO是一个基于云的平台，它将瓣膜病变的四个计算机辅助诊断（CADx）模块和八个关键测量结合到一个单一的，全面的心脏超声软件包中，该软件包自动生成分析，解释和计费报告。CARDIO使具有基本扫描技能的临床医生能够在几分钟内准确诊断床边最常见的心脏结构和功能参数的90%。

CARDIO was trained on hundreds of thousands of studies comprising over 24 million echo video clips. AISAP’s novel algorithms on POCUS devices has been validated in multi-national, multi-site, randomized, multi-reader, multi-case clinical trials at Mass General Brigham, Thomas Jefferson University Hospital, Mayo Clinic, Inova Fairfax Medical Campus, Crozer-Chester Medical Center and Stony Brook University Hospital..

CARDIO接受了数十万项研究的培训，其中包括2400多万个echo视频剪辑。AISAP在POCUS设备上的新算法已在Mass General Brigham、Thomas Jefferson University Hospital、Mayo Clinic、Inova Fairfax Medical Campus、Crozer Chester Medical Center和Stony Brook University Hospital的多国、多地点、随机、多读者、多病例临床试验中得到验证。。

AISAP CARDIO is indicated to provide diagnostic assessment and measurements of several key cardiac structural functional parameters, including: presence of valvular pathology (regurgitations of the mitral, tricuspid, aortic valves and aortic stenosis), and measurements of left ventricle ejection fraction (LVEF), right and left ventricular dimensions, right ventricular fractional area change (RV FAC), atrial areas, ascending aorta diameter, and inferior vena cava (IVC) diameter..

AISAP CARDIO可提供几个关键心脏结构功能参数的诊断评估和测量，包括：瓣膜病理（二尖瓣，三尖瓣，主动脉瓣和主动脉瓣狭窄的反流）的存在，以及左心室射血分数（LVEF）的测量，左右心室尺寸，右心室分数面积变化（RV FAC），心房面积，升主动脉直径和下腔静脉（IVC）直径。。

AISAP CARDIO is a vendor-agnostic, scalable solution that seamlessly integrates into the clinical workflow, as well as existing EHR/EMR and PACS systems.

AISAP CARDIO是一个与供应商无关的可扩展解决方案，可无缝集成到临床工作流程以及现有的EHR/EMR和PACS系统中。

About AISAP

关于AISAP

AISAP LTD is a pioneering company at the intersection of artificial intelligence and healthcare with a mission to transform healthcare delivery through its flagship product, AISAP CARDIO, which for the first time delivers POCAD™ (Point-of-Care Assisted Diagnosis). The platform enables clinicians to perform comprehensive, AI-powered ultrasound diagnostics anywhere, anytime, ensuring that advanced medical care is accessible at the patient’s bedside, whether in a hospital, clinic or rural setting..

AISAP有限公司是人工智能和医疗保健交叉点的一家开创性公司，其使命是通过其旗舰产品AISAP CARDIO转变医疗保健服务，AISAP CARDIO首次提供POCAD™（护理点辅助诊断）。该平台使临床医生能够随时随地进行全面的人工智能超声诊断，确保无论是在医院、诊所还是在农村地区，患者床边都可以获得先进的医疗护理。。

AISAP’s intuitive and secure SaaS platform is designed to empower healthcare providers by streamlining diagnosis processes, enhancing clinical efficiency, and improving patient outcomes.

AISAP直观而安全的SaaS平台旨在通过简化诊断流程，提高临床效率和改善患者预后来增强医疗保健提供者的能力。

Please visit

请访问

www.aisap.ai

网站：www.aisap.ai

for more information or to book a demo. Follow AISAP on

了解更多信息或预订演示。遵循AISAP on

LinkedIn

LinkedIn

for more updates.

获取更多更新。

References

参考文献

Reisman, A. M., & Elmariah, S. (2024). A Review of 'Access to Care' Issues in Aortic Stenosis Patients: A Negative Report Card. Structural Heart.

Reisman，A.M.，&Elmariah，S.（2024）。主动脉瓣狭窄患者“获得护理”问题的回顾：阴性报告卡。结构性心脏。

https://doi.org/10.1016/j.shj.2024.100351

https://doi.org/10.1016/j.shj.2024.100351

Leon, M.B., Smith, C.R., Mack, M., et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-1607.

Leon，M.B.，Smith，C.R.，Mack，M。等人；合作伙伴试验调查员。经导管主动脉瓣植入术治疗无法接受手术的患者的主动脉瓣狭窄。英国医学杂志2010；363（17）：1597-1607。

Sethi, A., Elmariah, S., Gunnarson, C., et al. The cost of waiting for a transcatheter aortic valve replacement (TAVR) in medicare beneficiaries with severe aortic stenosis. Structural Heart (2024).

Sethi，A.，Elmariah，S.，Gunnarson，C。等人。严重主动脉瓣狭窄的医疗保险受益人等待经导管主动脉瓣置换术（TAVR）的费用。结构性心脏（2024）。

Das, P., Pocock, C., Chambers, J. The patient with a systolic murmur: severe aortic stenosis may be missed during cardiovascular examination. QJM 2000 Oct;93(10):685-8.

Das，P.，Pocock，C.，Chambers，J。患有收缩期杂音的患者：在心血管检查期间可能会错过严重的主动脉瓣狭窄。QJM 2000年10月；93（10）：685-688。